Voyager Therapeutics, Inc. (VYGR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.51+3.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VYGR
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(10.5) + peer(0.2*0.0) + term(0.0) → 3.66% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated August 6, 2026 entitled “Voyager Reports Second Quarter 2026 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 6…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated May 7, 2026 entitled “Voyager Reports First Quarter 2026 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto dul…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated March 9, 2026 entitled “Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersi…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated November 10, 2025 entitled “Voyager Reports Third Quarter 2025 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereun…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated August 6, 2025 entitled “Voyager Reports Second Quarter 2025 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated May 6, 2025 entitled “Voyager Reports First Quarter 2025 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto dul…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated March 11, 2025 entitled “Voyager Therapeutics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated November 12, 2024 entitled “Voyager Therapeutics Reports Third Quarter 2024 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the under…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated August 6, 2024 entitled “Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersi…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated May 13, 2024 entitled “Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigne…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated February 28, 2024 entitled “Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its beha…
Results of Operations and Financial Condition The Company is currently completing its reports of its operational and financial results for the year ended December 31, 2023. However, the Company estimates its preliminary unaudited cash and cash equivalents and marketable securities to be approximately $230.7 million as of December 31, 2023, and that its preliminary unaudited cash and cash equivalents and marketable securities as of December 31, 2023, as adjusted to give effect to anticipated r…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated November 6, 2023 entitled “Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the unders…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated August 3, 2023 entitled “Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersi…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated May 9, 2023 entitled “Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results”. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned…